Track the Merit Medical Systems INC share price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Merit Medical Systems INC has recorded 149 reports. Market capitalisation: €4.3bn. The latest transaction was filed on 21 May 2026 (Levée d'options). Among the most active insiders: Parra Raul Jr.. Every trade is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 149 declarations
Merit Medical Systems, Inc. (ticker: MMSI) is a U.S.-based medical device company listed on the NASDAQ in the United States. Founded in 1987, Merit has built its business around proprietary single-use devices used in interventional, diagnostic, and therapeutic procedures. The company is headquartered in South Jordan, Utah, and serves hospitals and physicians worldwide, making it a globally distributed healthcare technology supplier rather than a purely domestic U.S. player. ([merit.com](https://www.merit.com/?utm_source=openai)) From an equity analysis perspective, Merit is best viewed as a diversified niche medtech company with exposure across multiple procedure categories. The business is organized primarily into two operating segments: cardiovascular and endoscopy. Within cardiovascular, Merit offers a broad set of products for vascular access and intervention, including micropuncture kits, angiographic needles, introducer sheaths, guide wires, hemodynamic monitoring tools, and custom procedural solutions such as kits, trays, and packs. Its endoscopy segment supports gastrointestinal and related intervention workflows. Beyond those core areas, Merit’s products are used in cardiology, radiology, interventional oncology, critical care, nephrology, orthopedic spine, pulmonology, and other specialty settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/856982/000085698225000011/mmsi-20241231x10k.htm?utm_source=openai)) Merit’s competitive position is supported by breadth of product lines, a direct sales force, distributor relationships, and an emphasis on procedural solutions rather than standalone consumables. This model can deepen hospital relationships and improve stickiness, especially in clinical categories where safety, workflow efficiency, and physician preference matter. The company also highlights ongoing innovation as a central part of its strategy, suggesting a pipeline-driven approach to maintaining relevance in a crowded medtech landscape. ([sec.gov](https://www.sec.gov/Archives/edgar/data/856982/000085698225000011/mmsi-20241231x10k.htm?utm_source=openai)) Recent developments have been constructive. In 2024-2025, Merit introduced and expanded several products, including SCOUT MD and newer offerings such as basixSky, MIGHTYwire, Siege, Bearing nsPVA Express, and 10FoRe. A notable strategic move came in September 2024, when Merit entered into an agreement to acquire Cook Medical’s lead management portfolio and related assets, broadening its therapeutic footprint. More recently, the company’s 2026 quarterly update pointed to organic constant-currency revenue growth, while also acknowledging tariff headwinds, indicating a business that is still expanding but operating in a more complex cost environment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/856982/000085698225000017/mmsi-20250401xdef14a.htm?utm_source=openai))